Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions

(Adnkronos) - Collaboration brings together Gene2Cure's portfolio development capabilities and Viralgen's proprietary Aava™ platform to support the efficient progression of programs for rare and ultra-rare genetic conditions toward the clinic.
Leggi l’articolo completo su Adnkronos ↗
12 s al passaggio a Adnkronos ·
Minut.ba mostra titolo e breve attacco. Il testo completo è su Adnkronos.